Please tell me which amp I should get specifically like the brand and model. Thanks!
By: Pimpalicous
This is to inform you that you have won a prize money of ONE MILLION GREAT BRITAIN POUNDS STERLING(1,000,000..00) in
the YEAR 2008 YAHOO! promotion which is organized yahoo! INC .G MAIL and HOT MAIL for the introduction and Launching
of the new YAHOO! BETA MAIL and Windows Live Mail
Beta which all YAHOO! And HOT MAIL subscribers are required to switch to.
BRIEF WINNING INFORMATIONS:
YAHOO!&a mp; MICROSOFT WINDOWS,arranged and gathered all thee-mail addresses of the people that are active online,
among the millions that subscribe at YAHOO!,HOT MAIL.AOL and others we only selected ONE HUNDRED EMAILS FROM ALL OVER
THE WORLD(100)candidates as our winners after undergoing the random selection process through electronic balloting
System (E.B.S) without the candidate applied, we congratulate you for being one of the people selected.
PAYMENT OF PRIZE AND CLAIM
Winners shall be paid in accordance with his/her Settlement Center . Yahoo Prize Award must be claimed no later than 21 days from date of Draw Notification. Any prize not claimed within this period will be forfeited.
Stated below are your identification numbers:
IDENTIFICATION NUMBERS:
Batchnumber…….YBM-WBS-2008390AF
Reffnumber…….YBM-WBS-200804522AF
Winning number…..YBM-WBS-200878AF
We hope you`re enjoying your new Yahoo! Mail account and Hot mail account.
These numbers above fall within the United Kingdom agent`s Location file, you are requested to contact Mrs linda brown (United Kingdom Zonal coordinator) and send your Identification Numbers and Personal Information to her at her email:E-mail: zonalcoordinator@ymail.com
You are therefore advised to send the following information to him to facilitate them and process the transfer of your fund with the appointed paying bank.
Send your Identification Numbers/Your Personal Information to him so that he will proceed further for your prize claim
immediately:
PERSONAL INFORMATION
1. Full name……..
2. Country……….
3.Contact Address……
4..Telephone Number..
5. Marital Status……..
6. Occupation…….
7.Age…………
8.Sex…………
Congratulations!!Once again.
Please be warned : For security reasons, you are advised to keep your winning information confidential till your claims is processed and your money remitted to you in whatever manner you deem fit to claim your prize.
This is part of our precautionary measure to avoid double claiming and unwarranted abuse of this program by some unscrupulous elements
Yours Sincerely,
Mrs Linda brown.
United Kingdom Zonal Coordinator.
Mr.Richard Watson
United Kingdom Zonal Secretary General.
John Branscombe
Director of Security and Facilities
To SEARCH, VIEW and APPLY JOBS from your mobile phone, SMS
Disclaimer:
The sender estherv2008 of this email is registered with timesjobs.com as Data Point ( datap08@rediffmail.com, 18 Jameson Street, HU1 3HU ) and has accessed your resume on timesjobs.com. Please note that there is no charge for registering on Timesjobs.com. Products for which charges are payable are clearly indicated on the site. It is the sole responsibility of the candidate to verify the content of the mails sent by the employers/recruiters. Further, you are advised to make appropriate/thorough enquiries before acting upon any unsolicited mail that you may receive from any individual/firm/company, asking for advance payment for any service that they may claim to be offering. Timesjobs.com does not vouch/guarantee for any such offers made by the above said parties.
The responsibility of checking the authenticity of offers/correspondence lies with you.
If you consider the content of this email inappropriate or spam, you may report abuse by forwarding this email to: timesjobs@timesgroup.com
Please note that timesjobs.com does NOT endorse any requests for money payments, or sharing of bank account details.
Legal Disclaimer:
This Website/ E-mail are vulnerable to data corruption, interception, tampering, viruses as well as delivery errors and we do not accept liability for any consequence that may arise therefrom
By: komal P
This month, the Agency for Healthcare Research and Quality issued a sweeping review of prostate cancer treatments, including surgical removal, radiation, hormone therapy and so-called watchful waiting, which involves careful monitoring but no active treatment until the cancer shows signs of growing.
Because none of these treatments emerged as superior, the agency came to the troubling conclusion that it could not recommend one over the others.
“Having been involved in this area for a long time, it was not shocking, but it is disappointing,” said Dr. Timothy J. Wilt, lead researcher on the report, from the Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research. “Information is really lacking to determine whether over all one treatment is more effective and preferred.”
Prostate cancer is the single most common cancer in the United States and the second most lethal among men after lung cancer. In 2008, the American Cancer Society estimates, 186,320 men will learn that they have it and 28,660 will die from it. The estimates for breast cancer are 182,460 and 40,480.
Prostate cancer is often diagnosed with a blood test that looks for prostate-specific antigen, P.S.A. There is widespread consensus that the test casts too wide a net, resulting in overdiagnosis and overtreatment. And the treatment can be devastating, leaving men impotent, incontinent or both.
The reasons behind the lack of data on prostate cancer are complex. A lack of financing and advocacy have roles. But so does the fact that prostate tumors grow slowly and can take 10 or more years to turn deadly. Not only does that make the disease particularly expensive and time consuming to study, but it is also a built-in disincentive for the drug industry, which typically has patent protection from 7 to 20 years.
A bigger obstacle to finding answers may be the patients, who have long been reluctant to participate in clinical trials, and their doctors, who tend to scorn such trials because they are already convinced that their chosen treatment is the best option.
One major clinical trial called Spirit, for Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial, would have compared surgical removal with brachytherapy, which involves implanting radioactive seeds. Just 56 of the 1,980 needed patients enrolled, and the trial was called off in 2004.
“Men don’t go into the clinical trials,” said Dr. Daniel P. Petrylak, associate professor of medicine and director of the genitourinary oncology program at the Columbia University Medical Center. “That’s the whole problem. Patients ask me all the time, ‘What is the best treatment?’ And I can’t give them an evidence-based approach for that, because we don’t have the data.”
Prostate doctors and patient advocates often compare their cause with that of the other leading sex-specific cancer: one of the largest prostate cancer support groups is called Us Too, a play on the Y-ME National Breast Cancer Organization. The dismal state of prostate cancer research and advocacy pales in comparison to the campaign against breast cancer.
“We’re at least a decade behind where breast cancer awareness is,” Thomas Kirk, president of Us Too, said. “We need to catch up. The lessons learned by breast cancer are the ones we’re trying to apply to prostate cancer.”
Prostate cancer groups have tried to replicate the success of the pink ribbon campaign with their own blue ribbon, but it has yet to gain widespread acceptance. A group advocating the development of imaging technology for prostate screening created a mascot, Prosty the Spokesgland, complete with a theme song, to the tune of “Frosty the Snowman.” Not surprisingly, it has not caught on, either.
Government spending for prostate cancer lags, too. In 2007, the National Cancer Institute spent an estimated $551.1 million on breast cancer research and $305.6 million on prostate cancer. For 2008, the Defense Department, which has a history of supporting health research, has allocated $138 million for breast cancer and $80 million for prostate cancer.
Prostate cancer researchers say the real problem is not so much financing as enlisting doctors and patients on board for clinical trials.
By 2010, men should have some answers from Pivot, the Prostate Cancer Intervention Versus Observation Trial, which is comparing surgical removal with watchful waiting. Results of studies looking at P.S.A. screening as well as the preventive benefits of the supplements vitamin E and selenium are also expected in a few years
By: Jason K
IN HTML
By: heather